Document is current
Any future updates will be listed below
-
Authors
Yoshida, Yusuke https://orcid.org/0000-0002-0774-0509
Hosokawa, Yohei https://orcid.org/0000-0002-8769-5524
Taogoshi, Takanori https://orcid.org/0009-0009-7896-3732
Oka, Naoya https://orcid.org/0000-0001-8894-6535
Kobayashi, Hiroki https://orcid.org/0009-0001-9168-5302
Kidoguchi, Genki https://orcid.org/0009-0001-0558-8814
Araki, Kei https://orcid.org/0000-0002-8922-1963
Ishitoku, Michinori https://orcid.org/0000-0003-3568-3430
Sugimoto, Tomohiro https://orcid.org/0000-0002-0968-9081
Mokuda, Sho https://orcid.org/0000-0002-8529-1016
Matsuo, Hiroaki https://orcid.org/0000-0002-8730-5389
Hirata, Shintaro https://orcid.org/0000-0002-2474-9943
-
Funding
Funding for this research was provided by:
JSPS KAKENHI (24K18642)
TSUCHIYA MEMORIAL MEDICAL FOUNDATION
Hiroshima University
- License Information
-
More Information
Article History
Received: 22 January 2026
Revised: 24 May 2026
Accepted: 26 May 2026
First Online: 6 June 2026
Declarations
:
: This study was approved by the Hiroshima University Certified Review Board (CRB6180006) (reference number: CRB2023-0006), and all patients provided written consent according to the Declaration of Helsinki. This study was registered with the Japan Registry of Clinical Trials (reference number: jRCT1061230085).
: Not applicable.
: Y. Yoshida received honoraria for the speakers bureau from Eisai, Asahi Kasei, Daiichi-Sankyo, AstraZeneca, Boehringer Ingelheim, AbbVie, Astellas, and Taisho Pharmaceutical Co. Ltd. S. Hirata received speaker fees, consultancy fees, research grants, and honoraria from AbbVie, Asahi-Kasei Pharma, Astellas, AstraZeneca, Ayumi, Bristol Myers Squibb, Boehringer Ingelheim, Celltrion, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead Sciences, Glaxo SmithKline, Janssen, Nihon-Kayaku, Novartis, Otsuka Pharmaceutical, Pfizer, Sandoz, Taisho, Tanabe Pharma, and UCB. The authors declare no conflicts of interest.
